Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy: Results From a Randomized, Double-Blind, Placebo-Controlled Trial
J Clin Psychiatry 2008;69(4):644-651
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Perinatal depression is common, and treatment
remains challenging. Depression has been reported to be associated with the
abnormality of omega-3 polyunsaturated fatty acids (PUFAs). A profound decrease
of omega-3 PUFAs in the mother during pregnancy is associated with the higher
demand of fetal development and might precipitate the occurrence of depression.
In this study, we examined the efficacy of omega-3 PUFA monotherapy for the
treatment of depression during pregnancy.
Method: From June 2004 to June 2006, we conducted an 8-week,
double-blind, placebo-controlled trial comparing omega-3 PUFAs (3.4 g/d) with
placebo in pregnant women with major depressive disorder (DSM-IV criteria). No
psychotropic agent was given 1 month prior to or during the study period. The
Hamilton Rating Scale for Depression (HAM-D) was scored every other week as the
primary measurement of efficacy, while the Edinburgh Postnatal Depression Scale
(EPDS) and Beck Depression Inventory (BDI) were secondary measures.
Results: Thirty-six subjects were randomly assigned to either
omega-3 PUFAs or placebo, and 33 among them were evaluated in more than 2
visits. A total of 24 subjects completed the study. As compared to the placebo
group, subjects in the omega-3 group had significantly lower HAM-D scores at
weeks 6 (p = .001) and 8 (p = .019), a significantly higher response rate (62%
vs. 27%, p = .03), and a higher remission rate, although the latter did not
reach statistical significance (38% vs. 18%, p = .28). At the study end point,
subjects in the omega-3 group also had significantly lower depressive symptom
ratings on the EPDS and BDI. The omega-3 PUFAs were well tolerated and there
were no adverse effects on the subjects and newborns.
Conclusions: Omega-3 PUFAs may have therapeutic benefits in
depression during pregnancy. In regard to the safety issue and
psychotherapeutic effect, as well as health promotion to mothers and their
newborns, it is worthy to conduct replication studies in a larger sample with a
broad regimen of omega-3 PUFAs in pregnant women with depression.
Trial Registration: clinicaltrials.gov Identifier NCT00618865